TD Cowen analyst Ritu Baral has maintained their bullish stance on GHRS stock, giving a Buy rating today.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ritu Baral’s rating is based on several factors that highlight GH Research’s potential for growth and development. The company is actively engaging with the FDA to address a remaining issue related to rat histology findings, which is crucial for lifting the clinical hold on their GH001 IND. GH Research is leveraging expert consultants and additional data to strengthen their case, indicating a proactive approach to regulatory challenges.
Furthermore, the company’s financial health appears robust, with a cash balance of $293.9 million, providing a runway into 2027. This financial stability, combined with the anticipated start of their Phase 3 TRD program in 2026, positions GH Research well for future advancements. These strategic efforts and financial positioning contribute to Ritu Baral’s Buy rating for GH Research’s stock.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.